AI Drug Development Eyes Obesity Treatment: The Significance of Insilico Medicine's 4 Trillion Won Technology Transfer to Lilly

Technology Transfer of Small-Molecule Candidate Compound
AI Drug Discovery Moves Beyond Platform and Candidate Identification
Recognized as a Key Asset in the Metabolic Disease Pipeline

Eli Lilly has signed a technology transfer agreement worth up to 4 trillion won with AI drug discovery company Insilico Medicine for its oral GLP-1 (glucagon-like peptide 1) receptor agonist. Industry analysts note that this deal is particularly significant as it marks the first time an AI-developed drug pipeline has entered the blockbuster metabolic disease segment, which is currently a mainstay of the global pharmaceutical and biotechnology markets, going beyond early-stage target identification.

According to industry sources on March 31, Eli Lilly has signed a global licensing and research & development (R&D) agreement with Hong Kong-based Insilico Medicine, valued at a total of $2.75 billion (approximately 4 trillion won). Under this agreement, Eli Lilly has secured exclusive rights for the development, manufacturing, and commercialization of a preclinical-stage drug candidate developed by Insilico Medicine. Insilico will immediately receive an upfront payment of $115 million (about 170 billion won) and is also entitled to milestone payments for development, regulatory approval, and commercialization stages, as well as royalties from future drug sales.

Currently, 'Wegovy' from Novo Nordisk and 'Mounjaro' from Eli Lilly dominate the global obesity treatment market, but both are peptide-based subcutaneous injectables, requiring patients to self-inject regularly, which is highly inconvenient. Peptides, which are protein fragments composed of amino acids, have structures similar to hormones in the body, resulting in excellent efficacy and target specificity. However, they are easily degraded by digestive enzymes and have low intestinal mucosal absorption, making it difficult to develop them as oral formulations. In contrast, small-molecule compounds have low molecular weight and simple structures, allowing them to easily pass through gastrointestinal cell membranes and be efficiently absorbed into the bloodstream. Drugs can be designed to withstand degradation in the digestive tract, and chemical synthesis enables mass production, dramatically lowering manufacturing costs.

Eli Lilly is also advancing late-stage clinical trials for "Orforglipron," an oral obesity drug based on small-molecule compounds that is intended for once-daily dosing and is nearing commercialization. However, the candidate discovered by Insilico Medicine has been designed to overcome the limitation of existing oral drugs that require daily administration, instead allowing for just one dose per week.

This technological breakthrough was made possible through Insilico's proprietary generative AI platform, "Pharma.AI," which enabled "multi-parameter optimization." Insilico's AI rapidly simulated countless chemical structures, ultimately identifying the optimal molecular structure that maximizes solubility and slows down the rates of metabolism and excretion in the body.

This deal is considered the first case of AI-developed drugs moving beyond early-stage target identification into the pipeline for obesity and metabolic diseases, which is regarded as the largest area in the global pharmaceutical and biotechnology markets. Until now, AI drug development had mainly focused on rare diseases or discovering anticancer agents for existing targets with expired patents, serving primarily to confirm technological feasibility. However, this large-scale technology transfer highlights that AI-based drug candidates are now emerging as core pipelines in the mainstream global pharmaceutical market.

Although the compound is still in the preclinical stage, Eli Lilly's decision to pay a substantial upfront sum demonstrates that major pharmaceutical companies now have strong confidence in the data reliability of AI-derived drug candidates. In the past, collaborations between global big pharma and AI drug developers, such as those involving Sanofi or Roche, were typically limited to exploring multiple new targets or conducting joint research at the platform level. This agreement, however, differs in that it directly proves the commercial potential of a single candidate molecule uniquely designed by AI, rather than focusing on the exploration of multiple targets. In South Korea, companies such as Samjin Pharm, Proteina, and Syntekabio are also developing new drugs using AI to reduce side effects and improve the efficacy of existing obesity treatments.

This content was produced with the assistance of AI translation services.